Abstract
Objective: Describe the impact of baseline factors on response to apomorphine sublingual film (APL-130277; APL) among patients with Parkinson's disease (PD) and “OFF” episodes in a pivotal controlled trial. APL was efficacious and generally well tolerated for the on-demand treatment of “OFF” episodes; the study met its primary endpoint of change in MDS-UPDRS Part III score at 30 minutes postdose at week 12 (least squares mean difference from placebo, -7.6 points; P=0.0002) and its key secondary endpoint of self-rated FULL “ON” response rate within 30 minutes postdose at week 12 (P=0.0426).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
